Menu

Tag: fluroquinolones

CPTR 2017 Workshop: Summaries, Slides, and Videos — Day 4

Welcoming Remarks Marco Schito (Critical Path Institute) Marco Schito kicked off the final day of CPTR’s 2017 Workshop by affirming the essential role of diagnostics in effective TB treatment, and contrasting that importance with a lack of corresponding investment in the field, despite such a compelling value proposition. Schito outlined reasons why diagnostic development has […]

May 17, 2017 Drug Development Events RDST Regulatory Science Research Resources Assay Development biomarkers clinical trials Community Engagement CPTR Workshop 2017 diagnostics drug development drug resistance fluroquinolones hollow fiber model next-generation sequencing ReSeq TB ReseqTB TB-PACTS

CPTR 2017 Workshop: Summaries, Slides, and Videos — Day 3

Welcoming Remarks Jim Gallarda (Bill & Melinda Gates Foundation) Jim Gallarda opened the day’s agenda by reminding participants of the importance of collaboration and that silos often act as the largest impediments to progress in global health. Video     Keynote Address: Learning from the Impact of the Drug-Diagnostic Development Strategy in Oncology Jan Trost […]

May 17, 2017 Drug Development Events RDST Regulatory Science Research Resources Assay Development biomarkers clinical trials Community Engagement CPTR Workshop 2017 diagnostics drug development drug resistance fluroquinolones hollow fiber model next-generation sequencing ReSeq TB ReseqTB TB-PACTS

CPTR 2017 Workshop: Summaries, Slides, and Videos — Day 2

Welcoming Remarks Mel Spigelman (TB Alliance) Mel Spigelman opened the second day of the workshop by introducing the day’s agenda and drawing attention to the personal stories of TB patients, reinforcing the driving force behind CPTR and all TB research and development efforts. Video   Driving Progress Through Regulatory Innovation – Learnings from Oncology and […]

May 17, 2017 Drug Development Events RDST Regulatory Science Research Resources Uncategorized Assay Development biomarkers clinical trials Community Engagement CPTR Workshop 2017 diagnostics drug resistance fluroquinolones hollow fiber model ReSeq TB TB-PACTS

CPTR 2017 Workshop: Summaries, Slides, and Videos — Day 1

Welcoming Remarks Jan Gheuens (Bill & Melinda Gates Foundation) & Debra Hanna (Critical Path Institute) Jan Gheuens opened the event by reflecting on the growth and progress of the CPTR Initiative, as well as forward to its ongoing work. He stressed that the direction of CPTR is truly determined by those who participate it in, […]

May 17, 2017 Drug Development Events RDST Regulatory Science Research Resources Assay Development biomarkers clinical trials Community Engagement CPTR Workshop 2017 diagnostics drug development drug resistance fluroquinolones next-generation sequencing ReSeq TB ReseqTB TB-PACTS

TB-PACTS Initiative Accepting Requests for Access

The TB-PACTS initiative represents a collaborative partnership between the Special Programme for Research and Training in Tropical Disease (TDR), the TB Alliance, St. George’s University of London, and Critical Path Institute (C-Path). The TB-PACTS data platform is designed to catalyze and accelerate innovative tuberculosis (TB) research by making aggregated Phase III TB clinical trial data […]

October 24, 2016 Drug Development Partner News Research Resources clinical trials drug development fluroquinolones TB-PACTS

CPTR and WHO Partner to Improve Understanding of Past Phase III TB Drug Trials

CPTR and the WHO Global TB Programme have partnered to help maximize the knowledge and understanding gained from completed Phase III TB drug clinical trials. The partnership will bring together an expert steering committee to analyze three contemporary Phase III trials (REMox TB, Rifaquin, and OFLOTUB). The collaboration will improve the drug development community’s understanding […]

December 21, 2015 Drug Development clinical trials fluroquinolones